Drug intelligence / Profile preview

LY-3108653

Development stage: Unknown
Lead developer: Transcenta

Overview

**LY-3108653** is an investigational drug initially developed by Eli Lilly & Co. and later licensed to Transcenta Holding. Limited public information is available on its specific mechanism of action, indications, or clinical progress, with its global highest R&D status reported as Pending.[1][3][5]

Beyond the preview

Go deeper on LY-3108653.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY-3108653.

Explore the full profile